A current view on the history of atypical antipsychotics

Danilov D.S.

doi:https://doi.org/10.17116/jnevro20171175185-93

Close metadata

Recommended articles:

An individual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102

Systemic bias in randomized clinical trials in different fields of medicine in 2014—2024: a narrative review. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):79-88

Black Acanthosis: Diagnosis and Treatment Issues. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):709-712

Abstract:

Based on the analysis of the original literature, the author for the first time systemizes the data on the story of atypical antipsychotic drugs. The history of introduction of the first atypical neuroleptics — clozapine and sulpiride, which launched the dichotomic development of psychopharmacology of atypical antipsychotics, is described. Historical facts on the introduction into practice of different sulpiride- and clozapine-like neuroleptics as well as the relationship of their history with the elaboration of dopamine and serotonin hypotheses of mechanisms of action of antipsychotics are presented. The author analyzes the efficacy and tolerability of treatment with different atypical neuroleptics. An importance of evidence-based medicine principles in the history of atypical antipsychotics is described. A significance of the history of some atypical and typical (pericyazine) neuroleptics in the evolution of conceptions on the validity of evidence-based medicine in psychiatry is evaluated. Main stages in the history of typical and atypical antipsychotics are determined.

Keywords:

atypical antipsychotics

clozapine

sulpiride

sulpiride-like antipsychotics

benzamide derivatives

D2/D3-antagonists

clozapine-like antipsychotics

5HT2-/D2-antagonists

neurochemical activity

dopamine theory

serotonin theory

evidence-based medicine

typical antipsychotics

pericyazine

history

Authors:

Danilov D.S.

Klinika psikhiatrii im. S.S. Korsakova;
kafedra psikhiatrii i meditsinskoĭ psikhologii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Close metadata

References:

Gross H, Langner E. Effect profile of a chemically new broad spectrum neuroleptic of the dibenzo-diazepine group (article in German). Wien Med Wochenschr. 1966;116(40):814-816.
Morozov PV. Interview with Jules Angsta. Dnevnik psikhiatra. 2012;3:1-5. (In Russ.).
Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva I. Letter: Clozapine and agranulocytosis. Lancet. 1975;2(7935):611. doi:10.1016/s0140-6736(75)90206-8
Alberts J, François F, Josserand F. Study of side-effects reported in patients under Dogmatil (article in French). Sem Hop. 1985;85:1351-1357.
Costall B, Naylor RJ. Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacologia. 1975;43(1):69-74. doi:10.1007/bf00437617
Avrutskii GYa, Neduva AA. Lechenie psikhicheski bol'nykh. M.: Meditsina. 1988. (In Russ.).
Gyermek L. Chlorpromazine: A serotonin antagonist? The Lancet. 1955;2:724. doi:10.1016/s0140-6736(55)92289-3
Leysen JE, Niemegeers CJE, Tollenaere JP, Laduron PM. Serotonergic component of neuroleptic receptors. Nature. 1978;272(5649):168-171. doi:10.1038/272168a0
Costall B, Fortune DH, Naylor RJ, Marsden CD, Pycock C. Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology. 1975;14(11):859-868. doi:10.1016/0028-3908(75)90114-8
Mucci A, Nolfe G, Maj M. Levosulpiride: a review of its clinical use in psychiatry. Pharmacol Res. 1995;31(2):95-101. doi:10.1016/1043-6618(95)80053-0
Quereux C, Taurelle R, Tamborini A. Treatment of psycho-neuro-autonomic disorders of menopause: contribution of veralipride compared with a barbiturate sedative (proxibarbal) (article in French). Rev Fr Gynecol Obstet. 1987;82(7-9):523-528.
Silveira da Mota Neto JI, Soares BGO, Silva de Lima M. Amisulpride for schizophrenia. Cochrane Database Systematic Reviews. 2002;2. doi:10.1002/14651858.cd001357
Wang J, Sampson S. Sulpiride versus placebo for schizophrenia. Cochrane Database Systematic Reviews. 2014;4. doi:10.1002/14651858.cd007811.pub2
Bukatina EE, Grigor'eva IV, Smirnov OR. Clinical trial of tiaprid in mental illness at a later age. Sotsial'naya i klinicheskaya psikhiatriya. 1994;4(4):115-119. (In Russ.).
Snedkov EV. Atypical antipsychotics: the search for solutions to old and new problems. Psikhiatriya i psikhofarmakoterapiya. 2006;8(4):45-50. (In Russ.).
Spano PF, Govoni S, Trabucchi M. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv Biochem Psychopharmacol. 1978;19:155-165.
Titeler M, List S, Seeman P. High affinity dopamine receptors (D3) in rat brain. Commun Psychopharmacol. 1979;3(6):411-420.
Bunzow JR, Van Tol HH, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature. 1988;336(6201):783-787. doi:10.1038/336783a0
Sokoloff P, Giros B, Martres MP, Bouthenet M-L, Schwartz J-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990;347(6289):146-151. doi:10.1038/347146a0
Stahl SM. Novye dostizheniya v terapii shizofrenii. V kn.: Shizofreniya. Izuchenie spektra psikhozov. Red. Ensill R., Khollidei S., Khigenbottem Dzh. Per. s angl. M.: Meditsina; 2001.
Stahl SM. Stahl’l essential psychopharmacology: neuroscientific basis and practical applications (4th ed.). Cambridge: Cambridge University Press. 2013;608.
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives General Psychiatry. 1988;45(9):789-796. doi:10.1001/archpsyc.1988.01800330013001
Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry. 1993;150(11):1630-1638. doi:10.1176/ajp.150.11.1630
Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry. 1990;41(8):892-897.
Panteleeva GP, Tsutsul'kovskaya MYa, Belyaev BS. Clinical efficacy leponex according to an international study. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova. 1984;84(3):393-401. (In Russ.).
Nuller YuL, Mikhalenko IN, Nuller YuL, Mikhalenko IN. Shizoaffektivnye psikhozy. V kn.: Affektivnye psikhozy. L.: Meditsina; 1988. (In Russ.).
Shmukler AB. Modern approaches to the application of leponex. Sotsial'naya i klinicheskaya psikhiatriya. 1998;8(3):131-136. (In Russ.).
Mannocchi G, Pantano F, Tittarelli R, Catanese M, Ronchi FU, Busardò FP. Development and validation of a GC-MS method for the detection and quantification of clotiapine in blood and urine specimens and application to a postmortem case. Int J Anal Chem. 2015;1-5.
Carpenter S, Berk M, Adams CE, Borgeat F. Clothiapine for acute psychotic illness: a meta-analysis. S Afr Psychiatry Rev. 2003;6(3):12-16.
Bishnoi RJ, Jhanwar VG. Tolerability of zotepine in Indian patients: Preliminary experience. Ind Psychiatry J. 2010;19(2):130-131. doi:10.4103/0972-6748.90345
Dickenson R, Fenton M. Zotepine versus placebo for schizophrenia. Cochrane Database Systematic Reviews. 2013;7. doi:10.1002/14651858.cd010644
Bersani G, Grispini A, Marini S. Neuroleptic-induced extrapyramidal side-effects: clinical perspectives with ritanserin (R 55667), a new selective 5HT2 receptor blocking agent. Curr Ther Res. 1986;40:492-499.
Fleischhacker WW, Miller CH, Ehrmann H. Ritanserin in the treatment of neuroleptic-induced akathisia (abstract). Schizophr Res. 1990;3:47. doi:10.1016/0920-9964(90)90125-q
De Bleeker E, Verslegers W. Ritanserin in the treatment of negative symptoms in chronic schizophrenic patients. Abstracts of the 17th Congress of CINP (Vol. II). Japan: Kyoto; 1990.
Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van Laarhoven JH, Busard HL. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry. 1993;163:451-455. doi:10.1192/bjp.163.4.451
Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl). 1989;99(Ssuppl):18-27. doi:10.1007/bf00442554
Ceulemans DL, Gelders YG, Hoppenbrouwers ML, Reyntjens AJM, Janssen PAJ. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology (Berl). 1985;85(3):329-332. doi:10.1007/bf00428197
Avedisova AS. Adverse events during therapy with neuroleptics: side effects and complications. Psikhiatriya i psikhofarmakoterapiya. 2007;9(5):14-18. (In Russ.).
Danilov DS. Terapiya shizofrenii (atipichnye neiroleptiki i individual'naya organizatsiya lechebnogo protsessa). M.: Miklosh. 2010. (In Russ.).
Shmukler AB. Evidence-based research in psychiatry: an analysis of practical significance. Dnevnik psikhiatra. 2012;4:9-14. (In Russ.).
Martynikhin IA. Clinical approach and evidence-based medicine Part 1. Clash of paradigms. Dnevnik psikhiatra. 2013;2:7-9. (In Russ.).
Davtyan EN, Kudrya SV. A word in defence of the clinician (on the use of clinical research questionnaires in psychiatry). Psikhiatriya i psikhofarmakoterapiya. 2014;16(2):59-64. (In Russ.).
Wallis GG. Proceedings of a symposium on behavioural disorders held in Leeds (ed. F.A. Jenner). Dagenham. 1965;26.
Avrutskii GYa, Vovin RYa, Lichko AE i dr. Biologicheskaya terapiya psikhicheskikh rasstroistv. L.: Meditsina; 1975. (In Russ.).
Burdakov AN, Burdakova EV, Fesenko YuA. Neiroleptiki v detskoi psikhiatricheskoi praktike. SPb.: Elbi-SPb; 2007. (In Russ.).
Gindikin VYa, Gur'eva VA. Lichnostnaya patologiya. M.: Izdatel'stvo «Triada-Kh»; 1999. (In Russ.).
Tyrer P. Drug treatment of personality disorder. Psychiatr Bull. 22(4):242-244. doi:10.1192/pb.22.4.242
Berk M, Rathbone J, Mandriota-Carpenter SL. Clotiapine for acute psychotic illnesses. Cochrane Database Systematic Reviews. 2004;4. doi:10.1002/14651858.cd002304.pub2